Clinical Results of Laserscope Laser Treatments to be Presented at ASLMS Annual Meeting
April 05 2006 - 7:13PM
PR Newswire (US)
Clinical Representation in Aesthetics, Urology and Otolaryngology
SAN JOSE, Calif., April 5 /PRNewswire-FirstCall/ -- Laserscope
(NASDAQ:LSCP), a pioneer in the development and commercialization
of minimally-invasive medical devices, including medical lasers and
advanced fiber-optic delivery devices, will feature prominently its
two leading laser technology platforms, the Gemini(R) and
GreenLight PV(R) laser systems in a variety of research studies and
presentations at the American Society for Laser Medicine and
Surgery (ASLMS) 26th Annual Meeting, April 5 - 9, 2006 in Boston,
MA. "We are pleased to be the only company at the ASLMS Annual
Meeting to have clinical experts present data on our applications
in three disciplines: aesthetics, urology and otolaryngology. The
presentation of these important findings in this forum is an
excellent opportunity to further educate the marketplace about
Laserscope's superior technology, broad product applications and
numerous patient benefits," said Eric Reuter, President and Chief
Executive Officer of Laserscope. "In addition to updates on the
current urology and aesthetic product line-up and applications, we
are also pleased to see physicians from other specialties finding
potentially new applications for high power 532 nm wavelength laser
energy. We are looking forward to investigating the potential
market size, economics, and technological differentiation that new
applications may bring to the Company." Urology Two of the studies
presented will report on successful clinical results obtained by
urologists using the GreenLight PV laser system to treat benign
prostatic hyperplasia, or non-cancerous, enlarged prostate, that
affects over 2.5 million men in the United States and several times
this number internationally. In addition, another study will
examine the underlying technology of the GreenLight PV laser
system's treatment effects by observing changes in animal soft
tissues exposed to 532 nm laser energy. The PVP procedure using the
GreenLight PV laser system is a minimally- invasive alternative to
the Trans-Urethral Resection of the Prostate (TURP) surgical
procedure to treat benign prostatic hyperplasia. Over 120,000 PVP
procedures have been performed worldwide and long-term clinical
data has demonstrated that the PVP procedure offers the same
clinical outcomes as TURP without the side effects and at a reduced
cost. Investigators who will report their findings relating to the
GreenLight PV laser system include Po N. Lam, MD, and colleagues
from the University of Oklahoma ("High Power KTP Laser
Photo-Selective Vaporization Prostatectomy for Large Volume Benign
Prostactic Hyperplasia" and "High Power KTP Laser Photo-Selective
Vaporization Prostatectomy and Refractory Urinary Retention
Secondary to Benign Prostatic Hyperplasia"). Urologists with
extensive clinical experience using the GreenLight PV laser system
will also contribute other presentations at the ASLMS Annual
Meeting. Nathaniel M. Fried, MD, of the Johns Hopkins Medical
Institutions, Baltimore, MD, will give a Laser Innovation Lecture
on "The Future of Lasers in Urology." Alexis E. Te, MD, of the
Cornell University Weill Medical College, New York, NY, will
present a "State of the Art Lecture on Photo-Selective Vaporization
of the Prostate," and will also speak on the GreenLight PV laser
system in a Point-Counterpoint Session. Ricardo R. Gonzalez, MD,
and colleagues, also from the Weill Medical College, will discuss
"High-Power KTP Laser Photo-Selective Vaporization Prostatectomy:
The Cornell Experience." Aesthetics In the aesthetic medicine
section of the ASLMS, several studies will be presented examining
the Gemini's use of the 532 nm wavelength for treatment of facial
telangiectasia and rosacea, an acne-like skin condition affecting
about 13 million people in the United States. These studies reflect
increasing clinical interest in the Gemini 532 nm wavelength laser
technology. The Gemini, 532 nm wavelength, delivers the high-power,
green laser energy that clears redness faster and more effectively
than traditional pulsed dye lasers. The Gemini system's 10 mm laser
spot size is the largest available, enabling physicians to safely
and effectively provide rapid treatments of large surface areas.
The spot size is also continuously adjustable from 1 mm to 5 mm so
that tiny blood vessels can be eliminated more precisely than with
less targeted intense pulsed light systems. Dermatologists at the
ASLMS professional program will report new research on the
treatment of rosacea-associated erythema using the 532 nm
wavelength with the Gemini system. These findings will be presented
by Arielle Kauvar, MD, from the New York Laser and Skin Care
Center. The effects of Gemini's 532 nm wavelength versus the 595 nm
wavelength generated by the pulsed dye laser in the treatment of
facial telangiectasia and redness will also be discussed. This
study was conducted by Nathan Uebelhoer, MD, and Jeff Dover, MD, at
Skin Care Physicians of Chestnut Hill, NJ. Otolaryngology In
otolaryngology, L.M. Akst, MD, from Massachusetts General Hospital,
Wellman Laboratories of Photomedicine, Harvard Medical School,
Boston, MA will present "Soft-Tissue Effects of Pulsed-KTP Laser on
Excised Calf Vocal Folds." This innovative research supports the
recent introduction of pulsed KTP laser technology into the realm
of vocal cord surgery. About ASLMS The American Society for Laser
Medicine and Surgery (ASLMS) was founded in 1980 and is the world's
largest professional organization dedicated to promoting excellence
in patient care by advancing laser applications and related
technologies. The Society's membership includes physicians and
surgeons representing more than 45 medical specialties, nurses and
other allied health care professionals, physicists involved with
product development, biomedical engineers, biologists and equipment
manufacturers. The Society currently has over 3,000 members,
including approximately 550 members who are not in the United
States. The ASLMS 26th Annual Meeting will be held in the Sheraton
Boston Hotel and Hynes Convention Center. Laserscope will display
the Gemini laser system in Technical Exhibit #401. About Laserscope
Founded in 1984, Laserscope (NASDAQ:LSCP) is a pioneer in the
development and commercialization of minimally-invasive medical
devices, including medical lasers and advanced fiber-optic delivery
devices for physician offices, outpatient surgical centers and
hospitals. The Company's GreenLight(R) PV laser systems are used
for the Photoselective Vaporization of the Prostate (PVP) procedure
in the treatment of benign prostatic hyperplasia. The PVP procedure
is gaining acceptance as an alternative to Trans Urethral Resection
of the Prostate (TURP) for treatment of the enlarged prostate. For
more information about Laserscope, please visit
http://www.laserscope.com/. Laserscope is an aesthetics solutions
provider, delivering value-added technologies, products and
services to customers in a variety of medical specialties.
Laserscope's light-based products include the Gemini(R) dual
wavelength laser system, the Venus(TM) Erbium laser and the
Solis(TM) intense pulsed light system. For more information about
Laserscope's Aesthetics offerings, please visit
http://www.laserscope.com/aesthetic or contact Liz Newman, Director
of Aesthetic Marketing, at 408-943-0636 or . Safe Harbor Statement
This press release contains forward-looking information within the
meaning of Section 21E of the Securities Exchange Act of 1934, and
is subject to the safe harbor created by this section. These
forward-looking statements include expectations regarding
Laserscope's new product offerings, the market opportunity for our
aesthetic and surgical products and their competitiveness in that
market. These statements are subject to a number of risks and
uncertainties, including: uncertainties regarding introduction of
new technologies competitive to Laserscope's aesthetic and surgical
products and the degree to which our current and new products are
accepted by customers, which could affect the level of demand for
our products; and risks that patents and licenses that we hold may
be challenged, invalidated or circumvented or that we may become
the subject of intellectual property litigation. The matters
discussed in this press release also involve risks and
uncertainties described from time to time in Laserscope's filings
with the Securities and Exchange Commission. In particular, see the
Risk Factors described in Laserscope's most recent Annual Report on
Form 10-K. Copies of Laserscope's public disclosure filings with
the SEC, including the most recent Annual Report on Form 10-K and
the most recent forms 10-Q are available upon request from its
Investor Relations Department at its website at
http://www.laserscope.com/ and at the SEC's website:
http://www.sec.gov/. Laserscope assumes no obligation to update the
forward-looking information contained in this press release. At
Laserscope: At Financial Relations Board: Eric Reuter, President
& CEO Tricia Ross, Investor/Analyst Contact Derek Bertocci, CFO
(617) 520-7064 (408) 943-0636 Moira Conlon, General Inquiries (310)
854-8311 DATASOURCE: Laserscope CONTACT: Eric Reuter, President
& CEO, or Derek Bertocci, CFO, both of Laserscope,
+1-408-943-0636; or Investor/Analysts, Tricia Ross,
+1-617-520-7064, or General Inquiries, Moira Conlon,
+1-310-854-8311, both of Financial Relations Board, for Laserscope
Web site: http://www.laserscope.com/aesthetic Web site:
http://www.laserscope.com/
Copyright
Laserscope (NASDAQ:LSCP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Laserscope (NASDAQ:LSCP)
Historical Stock Chart
From Jul 2023 to Jul 2024